Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIV007 in nAMD or DME
NCT05698329Phase 1Completed
- Sponsor
- AiViva BioPharma
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of AIV007 in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME) (6 arms), sponsored by AiViva BioPharma. Primary endpoint: Adverse Events at 168 days. Started Mar 2023; status: completed.
02
Drugs
AIV007
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05698329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698329.